US Patent 11839596 Treatment of vasculopathy with prostacyclin and mesenchymal stem cells
Patent 11839596 was granted and assigned to United Therapeutics Corp. on December, 2023 by the United States Patent and Trademark Office.
All edits
Edits on 13 Dec, 2023
Golden AI
Edits made to:
Infobox (+19 properties)
Article (+416 characters)
US Patent 11839596 Treatment of vasculopathy with prostacyclin and mesenchymal stem cells
Article
Patent abstract
Provided are methods for treating or preventing vasculopathy in a subject in need thereof, comprising administering to the subject a prostacyclin and a mesenchymal stem cell (MSC) or a MSC-conditioned culture medium or administering to the subject a MSC or a MSC-conditioned culture medium that has treated with prostacyclin. Pharmaceutical compositions suitable for such treatments are also provided.
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
Patent Inventor Names
Michael Wade0
Roger Jeffs0
Roger M. Ilagan0
Thomas Petersen0
Date of Patent
December 12, 2023
0Patent Application Number
174697450
Date Filed
September 8, 2021
0Patent Citations
Patent Primary Examiner
Find more entities like US Patent 11839596 Treatment of vasculopathy with prostacyclin and mesenchymal stem cells
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
